查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1590911

頭頸癌藥物市場：按產品、藥物類別和最終用戶 - 2025-2030 年全球預測

Head & Neck Cancer Drugs Market by Product (Bleomycin, Cetuximab, Docetaxel), Drug Class (Chemotherapy, Immunotherapy, Radiation therapy), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年頭頸癌治療市值為13.5億美元，預計到2024年將達到15.6億美元，複合年成長率為15.43%，預計到2030年將達到37億美元。

頭頸癌藥物的範圍和定義包括為治療口腔、喉、咽、鼻腔和唾液腺惡性而開發的藥物治療。這些治療包括化療、標靶治療和免疫治療，旨在抑制癌症生長和擴散。由於吸菸、飲酒和人類乳突病毒（HPV）感染等危險因子導致頭頸癌發病率不斷上升，這凸顯了對這些藥物的需求，這需要有效的治療解決方案。最終用途主要是醫院、腫瘤中心和研究機構，應用範圍從早期治療到轉移性疾病的管理。市場成長受到人口老化、藥物配方進步以及癌症治療意識增強的顯著影響。個人化醫療的引進和生技藥品的發展正在創造新的機遇，公司正在投資研發以開發副作用較少的標靶治療。其中包括單株抗體和免疫查核點抑制劑，它們在臨床試驗中顯示出有希望的結果。

主要市場統計
基準年[2023] 13.5億美元
預測年份 [2024] 15.6億美元
預測年份 [2030] 37億美元
複合年成長率（%） 15.43%

然而，市場開拓面臨藥物開發成本高、法律規範嚴格、治療副作用限制患者依從性等挑戰。此外，缺乏早期檢測技術常常導致診斷較晚，使治療效果複雜化。需要創新的領域包括加強聯合治療、將人工智慧融入藥物發現以及開發用於早期檢測和個人化治療的新型生物標記。透過專注於這些領域，我們可以透過改善治療結果和擴大治療選擇來實現業務成長。隨著技術的不斷進步和治療通訊協定的不斷發展，市場充滿活力，需要採取積極主動的方法來應對競爭壓力並滿足不斷變化的患者需求。

市場動態：快速發展的頭頸癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變頭頸癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球頭頸癌發生率上升
    • 增加政府和私部門的癌症治療舉措
    • 頭頸癌藥物的核准增加
  • 市場限制因素
    • 藥品費用高
  • 市場機會
    • 頭頸癌藥物優惠報銷制度
    • 後期管道藥物開發的新投資
  • 市場挑戰
    • 與藥物攝取相關的副作用

波特五力：駕馭頭頸癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對頭頸癌藥物市場的影響

外部宏觀環境因素在塑造頭頸癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解頭頸癌治療藥物市場的競爭狀況

頭頸癌治療藥物市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 頭頸癌藥物市場定位矩陣供應商績效評估

FPNV定位矩陣是評估頭頸癌治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪頭頸癌藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，頭頸癌藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地頭頸癌的發生率正在上升
      • 政府和私部門加強癌症治療力度
      • 提高頭頸癌藥物的核准率
    • 抑制因素
      • 藥品高成本
    • 機會
      • 頭頸癌藥物的優惠報銷
      • 後期管道藥物開發的新投資
    • 任務
      • 與藥物攝取相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章頭頸癌治療市場：依產品

  • 博來黴素
  • Cetuximab
  • 多西紫杉醇
  • Erbitux（Cetuximab）
  • Hydrea（羥基尿素）
  • 羥基尿素
  • Keytruda（Pembrolizumab）
  • 胺基甲基葉酸
  • 納武單抗
  • Opdivo（納武單抗）
  • Pembrolizumab
  • Taxotere（多西紫杉醇）
  • Trexol（胺基甲基葉酸）

第7章依藥物類別分類的頭頸癌治療藥物市場

  • 化療
  • 免疫療法
  • 放射治療
  • 外科手術
  • 標靶治療

第8章頭頸癌藥物市場：依最終用戶分類

  • 癌症研究組織
  • 診所
  • 醫院

第9章北美及南美頭頸癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區頭頸癌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲頭頸癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Merck & Co., Inc.
  • NEC Corporation
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-43676CF4239E

The Head & Neck Cancer Drugs Market was valued at USD 1.35 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 15.43%, to USD 3.70 billion by 2030.

The scope and definition of head and neck cancer drugs encompass pharmaceutical treatments developed to manage malignancies of the oral cavity, larynx, pharynx, nasal cavity, and salivary glands. These treatments include chemotherapy, targeted therapy, and immunotherapy, designed to inhibit cancer growth and spread. The necessity for these drugs is underscored by the rising incidence of head and neck cancers, driven by risk factors such as tobacco use, alcohol consumption, and human papillomavirus (HPV) infection, which necessitate effective therapeutic solutions. Applications extend from early-stage treatment to metastatic disease management, with end-use primarily in hospitals, oncology centers, and research institutes. Market growth is significantly influenced by the aging population, advancements in drug formulations, and increasing awareness of cancer treatments. The introduction of personalized medicine and development of biologics are creating new opportunities, with companies investing in R&D to develop targeted therapies with fewer side effects. These include monoclonal antibodies and immune checkpoint inhibitors that have shown promising results in clinical trials.

KEY MARKET STATISTICS
Base Year [2023] USD 1.35 billion
Estimated Year [2024] USD 1.56 billion
Forecast Year [2030] USD 3.70 billion
CAGR (%) 15.43%

However, market expansion faces challenges such as high drug development costs, stringent regulatory frameworks, and adverse side effects of treatments that limit patient compliance. Furthermore, the lack of early detection techniques often leads to late-stage diagnoses, complicating treatment efficacy. Areas ripe for innovation include the enhancement of combination therapies, integration of AI in drug discovery, and the development of novel biomarkers for early detection and treatment personalization. Focusing on these areas can drive business growth by improving treatment outcomes and expanding therapeutic options. The market is dynamic, driven by continuous technological advancements and evolving treatment protocols, necessitating a proactive approach to navigate competitive pressures and meet evolving patient demands.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Head & Neck Cancer Drugs Market

The Head & Neck Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of head and neck cancer all across the globe
    • Rise in government and private body initiatives for cancer treatment
    • Increased approval for head & neck cancer drugs
  • Market Restraints
    • High cost of the drugs
  • Market Opportunities
    • Favorable reimbursements for head and neck cancer drugs
    • New investments for developing late-stage pipeline drugs
  • Market Challenges
    • Adverse effect associated with the consumption of the drug

Porter's Five Forces: A Strategic Tool for Navigating the Head & Neck Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Head & Neck Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Head & Neck Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Head & Neck Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Head & Neck Cancer Drugs Market

A detailed market share analysis in the Head & Neck Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Head & Neck Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Head & Neck Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Head & Neck Cancer Drugs Market

A strategic analysis of the Head & Neck Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Head & Neck Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, BeiGene Ltd., Biocon Limited, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Merck & Co., Inc., NEC Corporation, Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Head & Neck Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Bleomycin, Cetuximab, Docetaxel, Erbitux (Cetuximab), Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate, Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere (Docetaxel), and Trexall (Methotrexate).
  • Based on Drug Class, market is studied across Chemotherapy, Immunotherapy, Radiation therapy, Surgery, and Targeted Therapy.
  • Based on End User, market is studied across Cancer Research Institutes, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of head and neck cancer all across the globe
      • 5.1.1.2. Rise in government and private body initiatives for cancer treatment
      • 5.1.1.3. Increased approval for head & neck cancer drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable reimbursements for head and neck cancer drugs
      • 5.1.3.2. New investments for developing late-stage pipeline drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effect associated with the consumption of the drug
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Head & Neck Cancer Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Bleomycin
  • 6.3. Cetuximab
  • 6.4. Docetaxel
  • 6.5. Erbitux (Cetuximab)
  • 6.6. Hydrea (Hydroxyurea)
  • 6.7. Hydroxyurea
  • 6.8. Keytruda (Pembrolizumab)
  • 6.9. Methotrexate
  • 6.10. Nivolumab
  • 6.11. Opdivo (Nivolumab)
  • 6.12. Pembrolizumab
  • 6.13. Taxotere (Docetaxel)
  • 6.14. Trexall (Methotrexate)

7. Head & Neck Cancer Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Immunotherapy
  • 7.4. Radiation therapy
  • 7.5. Surgery
  • 7.6. Targeted Therapy

8. Head & Neck Cancer Drugs Market, by End User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Head & Neck Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Head & Neck Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Head & Neck Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. BeiGene Ltd.
  • 5. Biocon Limited
  • 6. Bristol-Myers Squibb Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Gilead Sciences, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Incyte Corporation
  • 11. Merck & Co., Inc.
  • 12. NEC Corporation
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. HEAD & NECK CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. HEAD & NECK CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEAD & NECK CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEAD & NECK CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY BLEOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CETUXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY ERBITUX (CETUXIMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDREA (HYDROXYUREA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY KEYTRUDA (PEMBROLIZUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY OPDIVO (NIVOLUMAB), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TAXOTERE (DOCETAXEL), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TREXALL (METHOTREXATE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEAD & NECK CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SOUTH KOREA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. TAIWAN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. THAILAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. VIETNAM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 95. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. DENMARK HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. EGYPT HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. FINLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. FRANCE HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. GERMANY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. ISRAEL HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. ITALY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. NETHERLANDS HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. NIGERIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. NORWAY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. POLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. QATAR HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. RUSSIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SAUDI ARABIA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH AFRICA HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. SPAIN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. SWEDEN HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. SWITZERLAND HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. TURKEY HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED ARAB EMIRATES HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM HEAD & NECK CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. HEAD & NECK CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 159. HEAD & NECK CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023